Bimekizumab in patients with psoriatic arthritis

The monoclonal antibody bimekizumab may be safe and effective in patients with psoriatic arthritis.

In the BE OPTIMAL and BE COMPLETE phase III trials, published in ACR Open Rheumatology, researchers recruited biologic-naive patients and those with an inadequate response to tumor necrosis factor inhibitors. The patients were randomly assigned to receive either 160 milligrams of bimekizumab every four weeks, adalimumab, or placebo.

After a follow-up of 52 weeks, the researchers found that a higher proportion of the patients who received bimekizumab achieved a response to therapy, complete skin clearance and minimal disease activity, regardless of their use of methotrexate.

The rates of treatment-emergent adverse events were similar between the patients in the bimekizumab group who used or didn’t use methotrexate. Most adverse events were mild to moderate.

Read more: ACR Open Rheumatology

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.